Term ends Jan 4, 2033 · High confidence
20-year base term ends Jan 4, 2033
Held by Neurobo Pharmaceuticals, Inc.
Filed Jun 29, 2018 as application 16/024,288 · Granted Jul 14, 2020
Base term, 20 years from filing
Today
2013
2033
Clock starts
Jan 4, 2013
Jan 4, 2013
Term ends
Jan 4, 2033
Jan 4, 2033
Granted
Jul 14, 2020
Jul 14, 2020
base term
fee events
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
3
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. 1 of 3 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jan 4, 2013, when application PCT/US2013/020317, the earliest non-provisional in its chain, was filed (this one was filed Jun 29, 2018) | Jan 4, 2033 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jan 4, 2033 | High confidence |
Partial family
| Application PCT/US2013/020317 | PCT application no patent term | no patent term |
| US 10,028,926 | Lapsed on the fee record Jul 2022 | Jul 2022 |
| US 10,709,678 | this patent Jan 2033 | Jan 2033 |
Partial: 1 of the 3 has no file history here, so its row comes from the patent's own record or names the application alone. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 24, 2018 Reel 46953, frame 43 | Bisgaier, Charles L. | Michigan Life Therapeutics, LLC | Assignment of Assignor's Interest |
| Sep 24, 2018 Reel 46953, frame 98 | Michigan Life Therapeutics, LLC | Gemphire Therapeutics Inc. | Merger |
| Mar 11, 2020 Reel 52151, frame 108 | Gemphire Therapeutics Inc. | Neurobo Pharmaceuticals, Inc. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Jan 2033
Term ends Jan 4, 2033. Maintenance fees still fall due before then
Citations
0
later US patents cite this one
That is below the median of utility patents granted in 2020 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.